ATMI introduces sterile Pyrofree vials
Cost-effective, ready-to-use vials are guaranteed to be both pyrogen-free and sterile upon delivery
ATMI, a global technology company and leader in single-use bioprocess solutions, has introduced a line of pyrogen-free vials in collaboration with Disposable Lab (D-Lab), a Bordeaux, France-based contract-manufacturing company. Designed to meet biopharmaceutical filling and final packaging needs, the patent-pending Pyrofree vials are said to be the only cost-effective, ready-to-use vials guaranteed to be both pyrogen-free and sterile upon delivery.
Pyrogens induce rapid onset of fever with the potential to cause sepsis or progressive septic shock if they enter a patient's bloodstream. This makes it critical to ensure that pyrogens are not present in biopharmaceutical products. The most common techniques to remove pyrogens are either inactivation or destruction of the molecule through depyrogenation.
'We have come together with D-Lab to offer this comprehensive solution in support of our customers' end goal of advancing patient health and safety,' said Senior Vice President and General Manager of ATMI LifeSciences, Mario Philips. 'Pyrofree vials can be incorporated into ATMI's existing ultra-clean sterile packaging and fill/finish technologies, or used independently.'
ATMI subjects all Pyrofree vials to a thorough depyrogenation process that includes washing (with water for injection) and heating the vials to high temperatures in a polyether ether ketone (PEEK) bag to achieve a three-log reduction. Process specifications can be further modified based on customer requests.
Pyrofree vials are made to withstand the high temperatures during depyrogenation and sterilisation. After these steps, the vials are double-vacuum-packed in a PEEK bag for tamper-evidence, as well as to maintain sterility and guarantee no external contact. A third PE/PA film layer is added to the packaging under vacuum in a Class C cleanroom to protect the vials from any breakage during transportation and eliminate the need for a support tray.
'Pyrofree brings several clear benefits including the most cost-effective solution on the market, scalability from small to commercial-scale batches, and availability in both moulded and tubular formats,' said Jean-Pascal Zambaux, inventor of Pyrofree and majority owner of D-Lab. 'The vials may also be used for commercial safety stocks of injectables, and feature sizes up to 1 litre.'